PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Development of Effective, Novel Treatments Critical to Ensure Growth in the European Bladder Cancer Therapeutics Market - New analysis from Frost & Sullivan, European Bladder Cancer Therapeutics Markets, finds that the market earned revenues of $128.3 million in 2006 and estimates this to reach $163.2 million in 2013
Development of Effective, Novel Treatments Critical to Ensure Growth in the European Bladder Cancer Therapeutics Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/10/05 - New analysis from Frost & Sullivan, European Bladder Cancer Therapeutics Markets, finds that the market earned revenues of $128.3 million in 2006 and estimates this to reach $163.2 million in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

None of the developments in the bladder cancer area have improved the long-term survival rate of patients, with research results also remaining disappointing. Patients still die from muscle invasive disease, despite aggressive therapy with curative intent. Median survival after chemotherapy is usually 14 months. Moreover, no new drugs have entered the market over the past two decades, encouraging the scope for newer and more effective bladder cancer therapeutics.

New analysis from Frost & Sullivan (pharma.frost.com), European Bladder Cancer Therapeutics Markets, finds that the market earned revenues of $128.3 million in 2006 and estimates this to reach $163.2 million in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the European Bladder Cancer Therapeutics Market, send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore[.]frost.com with your full name, company name, title, telephone number, email address, city, state and country. We will send you the information through email upon receipt of the above information.

“There is a clear medical need for enhanced treatment options to manage the disease, as five-year survival rates in patients receiving conventional systemic therapy for metastatic disease are poor,” notes Frost & Sullivan Programme Leader Paljit Mudhar. “There is a huge unmet need for novel treatments that improve survival or increase the therapeutic ratio of systemic therapy.”

Emerging therapeutic options cover new cytotoxic drugs, targeted therapies and biological treatments, which include gene therapy. The market will benefit immensely if newer treatments can offer greater clinical efficacy compared to existing alternatives. In particular, novel forms of therapy are much needed for patients with metastatic disease, since current treatment regimes include only chemotherapy and/or radiotherapy that offer significant benefits to less than fifty per cent of patients.

However, products currently in the pipeline for bladder cancer are unlikely to dramatically change the competitive landscape over the long term, as they do not offer substantial improvement or change compared to current treatments. As a result of limited products in the pipeline in the phase III stage, the compound annual growth rate (CAGR) for the market is low.

“The European bladder cancer therapeutics market is likely to be considerably impacted from 2013 onwards, when drugs such as Tykerb (monoclonal antibodies) are likely to enter the market for this indication,” adds Mudhar. “Sizeable growth is expected, but this will be determined primarily by the acceptance and uptake rates in the market. Higher drug values within targeted therapy areas will be reflected in increased market revenues.”

In the meantime, numerous challenges threaten market growth, including development issues as a result of a lack of drugs that consistently prevent disease recurrence and progression. In addition, the high cost of bladder cancer treatment is placing intense pressure on healthcare providers. This is because costs associated with bladder cancer treatment are higher than that of other cancers since it tends to be a lifelong disease.

“Patients are subject to local recurrence over time, new tumour occurrences in surrounding areas and run the risk of disease progression with more invasive tumours,” explains Mudhar. “Treatment of bladder disease is costly, especially as it requires life-long follow up and management, resulting in increased pressure on healthcare providers to offer cost-effective care to patients.”

A key strategy for incumbent companies that have many mature product lines in their existing portfolio, such as chemotherapy and immunotherapy, is to explore different options and ways to deliver that particular drug. This can extend treatment opportunities and patient groups and help deliver the drug more effectively.

The strategic aim in the mature stage of the product life cycle is to win customers from competitors and boost usage. The value add, in this particular context, would be the drug delivery mechanism. For instance, ongoing research is attempting to improve the outcomes of mitomycin and BCG through different delivery mechanisms. Electromotive (intravesical electric current) is a drug delivery method currently being tested to deliver mitomycin and BCG more effectively.

European Bladder Cancer Therapeutics Markets is part of the Pharmaceutical & Biotechnology Growth Partnership Services, which also includes research in the following markets: European Urinary Incontinence Therapeutics, European Endometriosis Therapeutics, Blockbusters Going Off-patent: Opportunities for Generics Manufacturers in Europe and European Osteoarthritis. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Development of Effective, Novel Treatments Critical to Ensure Growth in the European Bladder Cancer Therapeutics Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Radhika Menon Theodore 
rmtheodore[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
The Float Space - Brisbane's First Float and Cryo Therapy Centre to Open This November
Thought Leaders Across the Healthcare Spectrum to Participate in Industry-Wide Survey
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Moriarty Physical Therapy of the Hudson Valley Expands with New Office in Lagrange, NY
Ultimate Medical Group Announces A New Regenerative Medicine Division
Dr. Amir Hanna Introduces New Medical Innovation Taking the Pain Out of Physical Therapy
Samitivej Children’s Hospital Transforms its Sukhumvit Campus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)